LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 6th Annual Microbiology Virtual Week, held on September 8-10, 2020!
Microbiology Virtual Week 2020 will offer a 3-day content-rich program offering invited lectures, thought-provoking discussions and posters to explore global developments for the prevention, diagnosis, and treatment of Infectious Diseases, discoveries in Microbiology & Immunology research to improve human, animal, and plant health, including virology, pathogenesis, genomics and epidemiology, microbial communities and biofilms, and research to find improved vaccines, diagnostics, and antiviral drugs for Influenza.
This year's event will include the following topics and tracks:
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event. The webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.
Like the 2019 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary and discuss results with interested colleagues through email. Plan now to have your poster included in the 2020 Microbiology Virtual Week. Submit your free abstract here.
Continuing Education - LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 50 credits.
Use #LRmicro to follow the conversation!
Dr. Alvarez is an Assistant Professor, in the division of Infectious Diseases at the Ichan School of Medicine at Mount Sinai, where his work focuses on the antibody-mediated mechanisms that correlate with HIV-1 suppression in HIV-1 controller patients. Dr. Alvarez has over 20 years experience conducting translational research in the infectious disease space. He is also the co-founder and CEO of Ichor Biologics, a pre-clinical biotechnology start-up that is dedicated to accelerating therapeutics in the infectious disease space. Dr. Alvarez received his BSc. in Molecular Biology & Biochemistry from Boston University, an MSc. in the Immunology of Infectious Disease from the London School of Hygiene and Tropical Medicine and a PhD from King's College London in Molecular Virology.
Dr. Bickhart is a Research Microbiologist/Bioinformatician at the US Department of Agriculture's Dairy Forage Research Center, where his work focuses on genome assembly of livestock species and their associated microbiomes. He has 10 years of experience in the field of Bioinformatics and Genome Informatics, and applies new technologies and algorithms to solve problems in agricultural production systems. Dr. Bickhart has been a contributor or team leader for many of the recently released reference genomes for agricultural species. The goal of this research is to improve the sustainability of agricultural systems by enabling predictive modeling of animal production with the inclusion of animal and microbial genomic information.
Jesse Bloom is a professor at the Fred Hutch Cancer Research Center and an Investigator of the Howard Hughes Medical Institute. The Bloom lab uses a mix of experiment and computation to study the evolution of viruses. Jesse received his PhD in Caltech where he worked with Frances Arnold, and then performed postdoctoral work with David Baltimore also at Caltech. Jesse started his own research group at the Fred Hutch in 2011.
Dr. Candice M. Brown is an assistant professor in the Department of Neuroscience and Rockefeller Neuroscience Institute at the West Virginia University School of Medicine. She received her PhD in Genetics and Genomics from Duke University and completed postdoctoral training at the University of California, Davis and the University of Washington. She joined the Center for Basic and Translational Stroke Research at West Virginia University in October 2014. The goal of her research is to understand how sex differences modify interactions between the brain and the immune system, with an emphasis on the brain's vascular system. Recent studies have focused on longitudinal changes in the gut microbiome and the enteric nervous system in animal models of sepsis, ischemic stroke, and Alzheimer's disease.
Cindy Chen originally comes from Taiwan. After completing her Bachelor Degree in Clinical Laboratory at Taipei Medical University, she continued her studies in Biochemistry and Molecular Biology at University of California, Davis, where her Ph.D. thesis was focused on thyroid hormone-regulated gene expression cascades during Xenopus laevis metamorphosis. She joined CellASIC as a scientist in 2009 which was later acquired by EMD Millipore in 2014. She has continued working with the microfluidic R&D team to create a portfolio of the microfluidic cell culture plates that can accommodate researchers from microbial to mammalian studies to monitor cellular responses to environmental perturbations under the microscopes for both short and long terms.
Dr. Costantini completed her doctorate degree in Biomedical Research at Albert Einstein College of Medicine in New York. Dr. Costantini's research focus integrates her background in cellular and molecular biology and virology with high-resolution microscopy approaches. At North Carolina Central University, Dr. Costantini's research lab studies the replication and lifecycle of human herpesvirus, Kaposi's Sarcoma Herpesvirus. More specifically, the viral DNA replication machinery and the factors that may influence viral replication.
Dr. James Crowe is Director of the Vanderbilt Vaccine Center and the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology and Immunology at Vanderbilt. His laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging infections. His research group uses a very broad array of techniques including molecular and cellular biology, single-cell biology and synthetic genomics, state-of-the-art imaging and flow cytometry, bioinformatics, and bioengineering approaches to attack scientific problems at the forefront of immunity research. The group has been recognized widely as a leader in antibody sciences, for instance as the Best Academic Research Team, 11th Annual Vaccine Industry Excellence Awards, World Vaccine Congress, recipient of the 2019 Merck Future Insight Prize for Pandemic Preparedness, and large-scale research grants and contracts from NIH and DoD, including the DARPA Pandemic Prevention Program (P3).
I have spent two decades in the bioinformatics field exploring data of various types and have explored topics from Single-Cell transcriptomics to face detectors for Sea Lions. My primary research focus is HIV genetic variation and how it influences disease progression and cure strategies.
I started my undergraduate degree in computer science before transitioning into biology at St. Lawrence University where I focused on environmental ecology using satellite imagery analysis to estimate biodiversity field data to satellite images and obtained my BS degree. After a few years working as a microbiologist, I was formally trained in computational biology and bioinformatics while at Carnegie Mellon University for a MS degree, and then PhD at Drexel University. For the last 10 years I have been working as the Head of Bioinformatics in Dr. Garth Ehrlich's laboratory. I am responsible for the development of new data processing pipelines, and subsequent data analyses for cutting-edge DNA sequencing platforms including the Pacbio RSII/Sequel. These implementations consist of both currently published techniques, and novel analyses designed to answer questions specific to our research (mainly on chronic bacterial pathogens). Our work consists of analyzing high throughput genomics, novel microbiome techniques, and machine learning to tease out biological meaning from these enormous datasets.
Santiago Elena is CSIC professor and chairman of the Institute for Integrative Systems Biology (I2SysBio), where he is the head of the Evolutionary and Systems Virology group. In addition, he is an external professor at the Santa Fe Institute (NM, USA). He graduated in Biochemistry from the University of Valencia and did a PhD thesis on Evolutionary Genetics of RNA viruses. He did a postdoc in the Center for Microbial Ecology at Michigan State University and a sabbatical stay in the Section of Ecology, Evolution and Behavior at UC San Diego. His work has always focused on the study of the mechanisms by which RNA viruses adapt to their hosts and how this adaptation results in the manipulation of cellular resources for their own benefit. For this work, he combines experimental evolution, advanced molecular biology, molecular epidemiology, and mathematical modeling. Among other merits, he is an elected member of the European Organization for Molecular Biology (EMBO), the Chinese Academy of Agronomic Sciences (CAAS), and the American Academy of Arts and Sciences (AAA&S).
Gang Fang is an Associate Professor in the Genomics Department at Icahn School of Medicine at Mount Sinai. He is also part of the Icahn Institute for Genomics and Multiscale Biology. The Fang lab pioneered the fast growing field of bacterial epigenomics, and developed the foundational methods that enabled the effective use of Single Molecule Real-Time (SMRT) sequencing technology for direct detection of DNA modifications. Since 2012, his lab has characterized the epigenomes of hundreds of bacterial species, identifying novel epigenetic mechanisms regulating bacterial gene expression, virulence, biofilm formation and sporulation etc. Recently, his lab pioneered the use of DNA methylation for high resolution microbiome analysis. Dr. Fang received his PhD degree in University of Minnesota in 2012, his MS degree in University at Buffalo, 2007, and his BS degree in Fudan University, 2005. Dr. Fang received multiple awards including: Joint Mayo Clinic - IBM Research Traineeship (2007), Best Network Model Award, Sage Congress (2010), Walter Barnes Lang Fellowship (2011), Best Dissertation Award at University of Minnesota (2012), Kavli Frontiers in Science Fellow (2013), Nash Family Research Scholar, Friedman Brain Institute (2016), Hirschl Research Award, Irma T. Hirschl Trust (2018).
Ioan Filip is an Associate Research Scientist in Systems Biology, and a member of the Program for Mathematical Genomics at Columbia University. He received his Ph.D. in Mathematics from Columbia in 2016. At the Rabadan Lab, Ioan's work is focused on the genetic basis of the immune response to viral infections, as well as on the role of the immune system in cancer progression and treatment. Ioan is also interested in developing algebraic and topological methods to model both viral and tumor evolution.
Dr. Svetlana Y. Folimonova received her PhD in Microbiology from Moscow State University, Moscow, Russia. She held a postdoctoral position at the S. R. Noble Foundation, Ardmore, Oklahoma and a postdoctoral position at the University of Florida, Citrus Research and Education Center, Lake Alfred, Florida. Dr. Folimonova was appointed Assistant Professor of Plant Pathology at the University of Florida, Gainesville, Florida, in 2012. In 2016, she was promoted to Associate Professor. Dr. Folimonova's research program focuses on viral and bacterial pathogens of citrus, with the main emphasis on Citrus tristeza virus (CTV) and Candidatus Liberibacter asiaticus, a causal agent of citrus greening [Huanglongbing (HLB)]. Her primary research effort is concentrated on understanding the mechanisms of the infection process, host responses to the pathogens, improving methods of detection, and developing management strategies for these diseases. In 2020, Dr. Folimonova received a prestigious Syngenta Crop Protection Award from the American Phytopathological Society for her outstanding contributions to research on CTV and, specifically, for the elucidation of the mechanism of the CTV superinfection exclusion and for the research accomplishments on the development of the CTV-based vectors for expression of antimicrobial proteins for management of citrus greening. Dr. Folimonova also serves as Councilor for Plant Virology at the American Society for Virology.
Michael Goodin employs live-cell imaging to investigate the cellular biology of plant-adapted rhabdoviruses, and other RNA viruses. He has made seminal contributions particularly regarding the mechanism of nuclear transport of viral proteins, their ability to modify nuclear membranes, and identification of host factors implicated in cell-to-cell movement. He is presently focused on the identification and characterization of emerging plant viruses in Brazil, including the mite-transmitted coffee ringspot virus. Like zoonotic viruses, plant viruses, particularly those with arthropod vectors, share the ability to jump species barriers, which results in their “emergence” into new host populations. He conducted his postdoctoral research at the University of California-Berkeley, graduate research at The Pennsylvania State University, and received his undergraduate degree from Brock University. He communicates how fundamental principles of science are relevant to everyday life via original essays posted on his blog at greenorangecafe.org.
Dr. Graf has pioneered the work on several model system for beneficial bacteria-animal interactions including the light organ symbiosis of the bobtailed squid and the digestive tract symbiosis of the medicinal leech. His work combines the application of next generation sequencing, molecular genetics and microscopy to better understand the role the microbiome plays in the health and disease of animals. He was elected as a fellow of the American Academy of Microbiology and served as Vice President of the International Symbiosis Society. He is a professor in the Department of Molecular and Cell Biology at the University of Connecticut.
Dr. K. Leigh Greathouse is an Assistant Professor at Baylor University with appointments in Biology and Nutrition. Her background spands the fields of cancer biology, epidemiology, and nutrition. She recived her Ph.D. from the University of Texas and M.D. Anderson Cancer Center, and her M.P.H. from Johns Hopkins Bloomberg School of Public Health. She completed her postdoctoral training at the National Cancer Institute in the laboratory of Curtis Harris, where she discovered a novel microbiome-gene interaction in lung cancer. The focus of her laboratory at Baylor is on elucidating the relationship between diet and the microbiome and its impact on cancer etiology and treatment. The goals of the Greathouse lab are focused on 1) delineating the dietary factors that modify the microbiome and its function, 2) developing microbial multi-omic classifiers that improve stratification of patients for cancer treatment, and 3) identify key functional pathways and mechanisms of microbiota-host communication. Dr. Greathouse has received multiple awards for her work, including a Merit Award from the National Insitutes of Health, Excellence in Research Leadership, and Rising Star at Baylor Univeristy. Most recenlty, she was awarded a career development award from Department of Defense to study the relationsihp between diet and the microbiome in colon cancer treatment response and toxicity. Ultimately, the goal of her lab is to discover dietary factors and microbial targets for the development of clinical tools to prevent cancer development, and reduce morbidity and mortality from colon cancer.
Dr. Graham is Deputy Director and Chief of the Viral Pathogenesis Laboratory at the NIAID Vaccine Research Center. He has a BA from Rice University, an MD from the University of Kansas School of Medicine, and a PhD in Microbiology & Immunology from Vanderbilt University School of Medicine. His primary interests are vaccine development for viral diseases, viral pathogenesis, mechanisms of immunity, and pandemic preparedness. His laboratory has developed novel vaccines for RSV, influenza, Zika, and coronaviruses including the first COVID-19 vaccine and monoclonal antibody products to enter clinical testing.
Jonathan Jacobs, Ph.D., has 20 years of experience in bioinformatics, molecular genetics and microbial genomics. In 1999, he received his BSc. in plant biology from the University of Arizona and later his Ph.D. in molecular genetics and cell biology from the University of Maryland. Later, Dr. Jacobs received postdoctoral training at the NIH's National Cancer Institute, where his research focused on epigenetic control of gene expression in human oncology model systems. Following his postdoc, Dr. Jacobs joined MedImmune where he developed novel technologies in cell line engineering that resulted in multiple patent applications. In 2010, he joined MRIGlobal to build and lead a team focused on microbial forensics and pathogen genomics. Dr. Jacobs joined QIAGEN in 2018, and is the Director of Global Product Management, Genomic Analysis for QIAGEN Digital Insights, where he is directing the development of QIAGEN's CLC software portfolio, a widely used commercial bioinformatics platform.
Dr. Kanekiyo serves as Scientific Lead of the Influenza Program at the Vaccine Research Center (VRC), NIAID, NIH. In this role, he leads scientific research on basic, preclinical, and translational aspects of candidate influenza vaccines developed in the VRC. In addition, he is Head of Molecular Immunoengineering Unit, in which his team tackles complex immunology and vaccinology questions utilizing techniques in immunoengineering, protein engineering, molecular virology, synthetic biology, structural biology, and biochemistry. Dr. Kanekiyo is an immunologist, and a virologist who studies vaccine technologies, viral immunity, and host pathogen interaction. His work is centered on influenza virus, herpesvirus, and (re)emerging viruses. Dr. Kanekiyo obtained his D.V.M. from the Nihon University, Japan in 2002, and earned his Ph.D. in Veterinary Medicine with concentration on Molecular and Microbiology at the Nihon University Graduate School of Veterinary Medicine in 2006. Prior to the current appointment he was a postdoctoral fellow in the laboratory of Dr. Gary Nabel at the VRC focusing on HIV and influenza immunogen design. Dr. Kanekiyo is an inventor of several vaccine related technologies including the self-assembling nanoparticle-based influenza vaccines, that are currently evaluated in human phase I clinical trials.
Dr. Kurath has been a federal research microbiologist at the USGS Western Fisheries Research Center in Seattle since 1992, where she directs an active research group investigating viral fish pathogens of global importance. She has also been affiliate faculty at the University of Washington since 1994, where she is currently an affiliate professor in both the Pathobiology Graduate Program and the School of Aquatic and Fishery Sciences. Her work involves the epidemiology and evolution of fish rhabdoviruses that cause major disease burdens in Pacific salmon and trout species, with impacts in both conservation hatchery programs and intensive aquaculture industries. Based on 20 years of genetic typing of virus field isolates her group has conducted molecular epidemiology studies at local, regional, and international scales. Hypotheses developed from field observations are tested in controlled wetlab experiments in vivo, with molecular analyses to define the host-pathogen factors that drive ecological events. Current research topics include viral host specificity, viral fitness, viral displacement events, evolution of specialist and generalist virus lineages, molecular basis of virulence, and virulence evolution after host jumps. As a general strategy her work contributes to sound fish health management in the Pacific Northwest and the northern hemisphere, and also serves as uniquely tractable model systems for addressing questions of basic virology in vertebrate hosts.
Dr. Longbrake earned her MD and PhD degrees at the Ohio State University and then did a fellowship in neuroimmunology at Washington University. She is currently an Assistant Professor of Neurology at Yale University, where she directs the clinical and translational research program in neuroimmunology. Her current work focuses on the relationships between the microbiome/metabolome, multiple sclerosis, and the immunomodulatory medications used to treat the disease.
Dmitry Lyumkis began his cryo-EM career in 2008 working as a graduate student under the supervision of Bridget Carragher at the Scripps Research Institute. In 2014, he moved to the Salk Institute for Biological Studies to start an independent position as a Salk Helmsley Fellow, where he was later promoted to Assistant Professor in 2018. His group is interested in HIV structural biology and cryo-EM methods.
Amy Mathers, MD, D(ABMM) is a tenured Associate Professor of Medicine and Pathology at the University of Virginia. She acts as Clinical Director of the Adult Antimicrobial Stewardship Program and Associate Director of Clinical Microbiology for the University of Virginia Medical Center. She has focused much of her research on the urgent clinical problem of antimicrobial resistance in Enterobacteriaceae. Molecular characterization has included analysis of mobile resistance mechanisms with evaluation of plasmid evolution and mobility across species with next generation sequencing paired with more traditional techniques. With support from the Centers for Disease Control and Prevention she has investigated the role that the hospital plumbing environment can play in evolution and dissemination of carbapenemase genes.
Dr. Missel is the Director of Research and Development at QIAGEN, responsible for the continuous innovation of nucleic acid modification and amplification technologies and products, such as reagents and assays for QIAGEN's standard and real-time PCR, RT-PCR, HRM solutions, and, most recently, digital PCR. Dr. Missel received his Ph.D. in molecular biology and biochemistry from the Gene Center at the University of Munich. He has worked in various capacities in the biotechnology industry for more than 20 years.
Dr. Juliet Morrison is an Assistant Professor at the University of California Riverside. Her research combines immunological and virological methods with computational analysis to address questions at the host-pathogen interface. A major interest of the Morrison Lab is understanding how emerging and re-emerging viruses antagonize innate immune pathways to promote their replication. They also use virus-encoded interferon antagonists as tools to define previously unknown aspects of interferon signaling regulation. Another interest of Professor Morrison is using tissue deconvolution algorithms and immunological tools to study the dynamics of lung immune cell populations during influenza virus infections, and spleen and liver immune cell populations during dengue virus infections. Her goal is to translate these findings into host-targeted influenza and flavivirus therapeutics.
Dr. O'Hara has developed cutting edge next-gen sequencing-based technology for hospitals and spent five years commercializing this technology. She has led unprecedented, large-scale metagenomics work characterizing the microbiome of ambulances across the US, hospital environments, the urine microbiome, and SARS-CoV-2 samples. She completed a postdoc in health tech business at Cornell Tech (2018), a postdoc at Fordham University in Bioinformatics (2015), a PhD in Ecology and Evolutionary Biology at Stony Brook University (2014), and a BA at NYU (2005). Dr. O'Hara has published peer-reviewed articles in the fields of metagenomics, genomics, evolutionary biology and ecology in top ranked journals such as Molecular Ecology, Microbiome, and Evolution. Her work has been featured in GenomeWeb, Popular Science, the Huffington Post, and WIRED.
Dominic O'Neil has over 20 years of experience in the biotechnology industry. Before joining QIAGEN, he gained molecular biology expertise at several companies, including three years at the Whitehead/MIT Center for Genome Research in Cambridge, MA, where he participated in the completion of the initial draft of the human genome. Dominic joined Digene (which later became part of QIAGEN) in 2004 to work on new technology research and development, focusing in particular on sample preparation and diagnostic applications. In 2011, he joined the QIAGEN R&D group in Hilden as a Senior Scientist to work on solutions for next-generation sequencing. He is now the Director of R&D for Microbiome Product Development.
Peter Palese is a Professor of Microbiology and the Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai. His research is in the area of RNA-containing viruses with a special emphasis on influenza viruses. Specifically, he established the first genetic maps for influenza A, B, and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals). He was also a pioneer in the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses. This technique is crucial for the study of the structure/function relationships of viral genes, for investigation of viral pathogenicity and for development and manufacture of novel vaccines. An improvement of this technique has been effectively used by him and his colleagues to reconstruct and study the pathogenicity of the highly virulent, but extinct, 1918 pandemic influenza virus. Work in collaboration with Dr. Adolfo Garcia-Sastre has revealed that most negative strand RNA viruses possess proteins with interferon antagonist activity, enabling them to counteract the antiviral response of the infected host. In recent years most of the efforts by Dr. Palese and by his collaborators at Mount Sinai, Dr. Adolfo Garcia-Sastre and Dr. Florian Krammer, have been directed at developing a Universal Influenza Virus Vaccine. Since the beginning of the year there has been a shift in directions as work on COVID-19 has become central to the efforts by Dr. Palese. Dr. Palese is a Member of the National Academy of Sciences, a Member of the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, and a Fellow of the National Academy of Inventors
Dr. Rasmussen is a virologist studying host responses to infection by combining classical virology with modern systems biology approaches. Her research objectives are to identify host response signatures predictive of infection severity or disease outcome and host pathways to target drug development or repurposing. She is particularly interested in viruses that are highly pathogenic, newly emergent or likely to emerge because of climate change, land development, or ecological disruption. Dr. Rasmussen has employed Collaborative Cross (CC) mouse models, which provide an expanded range of disease presentations, to study viral disease characteristics. At the University of Washington, she developed a CC mouse model of Ebola virus disease, utilizing the diversity of CC mouse disease phenotypes to study genetic and transcriptomic factors underlying disease severity in humans. She is currently evaluating CC mouse models towards investigation of sex-specific host responses to viral infection, as well as to investigate disease presentation in other viruses that pose a major threat to global public health, such as dengue virus, influenza virus, and SARS-CoV-2. Ultimately, these host response profiles can be used for translational or biodefense applications, such as diagnosing infection, predicting disease severity, informing vaccine design, and developing or repurposing host-targeted drugs to impair virus replication or reverse pathology.
William Rawlinson is a clinician scientist recognized internationally for translational research into human CMV in pregnancy and other immune compromised clinical states. He established, and oversees, serology and virology clinical research programs, statewide transplant donor screening, and national quality programs for serology and biosecurity. The laboratory he directs studies pathogenesis of congenital CMV infection, clinical application of research findings to pregnant women and neonates, and novel antivirals. He is conjoint professor at UNSW with over 400 publications in basic research, diagnostic and clinical virology.
I am a Ph.D. candidate in Bioinformatics and Computational Biology at the University of Minnesota. My advisor, computer scientist Rui Kuang, and I are interested in discovering how high-throughput sequencing technologies can be used to understand the complex genetics of the KIR (killer-cell immunoglobulin-like receptors).
Professor Brajesh Singh is an internationally recognised expert in the field of functional ecology and soil biology. Through his fundamental research, his work identifies the quantitative relationships between soil biodiversity and ecosystem functions and how natural/anthropogenic pressures such as global change affect this. His applied research harnesses the knowledge gained in fundamental research to achieve increased farm productivity, sustainable development, environmental protection and food security. His research has advanced critical areas of ecosystem science, particularly linking soil biodiversity to key ecosystem functions and services and has developed tools to improve farm productivity and environmental sustainability. This includes climate adaptation tools for the agriculture industry, management solutions to increase soil organic matter, increased export market access for agriculture produces, and training for farmers, consultants and policy advisors in sustainable agriculture and the Sustainable Development Goals.
Dr. Melissa Smith is an Assistant Professor of Biochemistry and Molecular Genetics at the University of Louisville. She joined the faculty there in July of this year, after spending the prior four years managing the Genomics Technology Core team at the Icahn School of Medicine at Mount Sinai. Dr. Smith's personal research focuses on utilizing cutting edge genomics technologies to investigate host-pathogen interactions. Specifically, she has been using single molecule, real-time (SMRT) sequencing methods to define mechanisms of viral immune evasion and profile host immune repertoires for more than six years. Ongoing work in her laboratory utilizes the long, phased reads provided by SMRT sequencing to reconstruct and profile the incredibly complex immune loci in the human genome (HLA, Ig, TCR) as well as viral surveillance and evolution, including SARS-CoV2 and HIV.
Dr. Tyler Starr is an HHMI Damon Runyon Postdoctoral Fellow in Jesse Bloom's lab at the Fred Hutchinson Cancer Research Center in Seattle, Washington. He researches the molecular evolution of viral and immune genes, combining computational evolutionary analyses with high-throughput experimental assays to characterize the effects of amino-acid mutations on protein function. These experiments highlight biochemical constraints on protein function, inform the design of vaccines and antibody therapeutics, and illuminate the evolutionary forces that shape key viral and immune proteins.
The current goals of my research are to better understand lung immune responses during acute vs. chronic exposure to the opportunistic fungal pathogen Aspergillus fumigatus. During acute exposure, which is an infection model mimicking invasive pulmonary aspergillosis, our major focus is on the cytokine IL-22. Specifically, we investigate pathways that positively and negatively regulate IL-22 production as well as the antifungal immune pathways induced by IL-22. Themes in this area of investigation include common γ-chain cytokines, innate lymphocytes and eicosanoid biology. An important shift in my laboratory over the last several years has been focused on the identification of inflammatory biomarkers, immune cells and pathways in human lung diseases that correlate with functional decline, and bringing these observations back to experimental animal models to provide mechanistic insight (i.e. bedside-to-bench). To this end, during chronic exposure, which is a model of severe asthma with fungal sensitization as well as chronic fungal exposure during diseases such as cystic fibrosis, our major focus is on various inflammatory mediators we have identified in human subjects. Themes in this area of investigation include various IL-1 family members, unique chemokines and chitinases/chitinase-like proteins.
Imre Varju is a Fulbright Scholar in medical science and a Health Communication Specialist with nearly 10 years of experience working with Neutrophil Extracellular Traps, with a special focus on their contribution to immunothrombosis. He obtained his MD and PhD at Semmelweis University, Hungary, completed postdoctoral trainings at the Hungarian Academy of Sciences, the National Institute for Biological Standards for Control, UK and at Harvard Medical School, and obtained his MPH at Columbia University. On top, he has been working as a Health Education Strategist at FCB Health New York.
Professor Quan Wang is committed to using cryo-electron microscopy to study the composition and structure of important biomolecules and complexes of pathogenic microorganisms and the molecular mechanisms of host immune systems in response to pathogen infection. At the same time, he also works on the relevant anti-infective drugs screening and development.
Detlef Weigel, a German-American scientist, is currently Executive Director of the Max Planck Institute for Developmental Biology. He is a member of the US National Academy of Sciences, the German National Academy of Sciences Leopoldina and the Royal Society, and recipient of several scientific awards, most recently the Novozymes Prize of the Novo Nordisk Foundation. The first major finding from his lab was that an Arabidopsis gene could dramatically accelerate flowering of trees; this established a proof of concept for Arabidopsis genetics as a platform for biotechnological discoveries. His group later discovered the first plant microRNA mutant and identified the factor that we now know to be the long sought-after mobile flower-inducing signal. Detlef was also one of the first to exploit natural genetic variation for understanding how the environment affects plant development. In recent years, this work has come to incorporate questions at the interface of evolution and ecology: How can wild plants adapt to climate change, and how do they manage to keep their pathogens at bay? In this research, he draws on the fruits of a collaborative effort initiated over a decade ago to sequence the genomes of over 1,000 natural A. thaliana strains (The 1001 Genomes Project). Detlef has an extensive record of service to the scientific community, having served on a series of editorial and advisory boards. He is a forceful advocate of open access publishing and founding Deputy Editor of eLife. He is a co-founder of three biotech startups.
Eric Wommack graduated Summa Cum Laude from Emory University with bachelor degrees in Biological Sciences and Economics. Realizing that the number of economic theories always exceeds the number of economists and ignoring significant opportunity costs, he chose the more glamorous, albeit indigent, path of graduate work in the life sciences. After graduating from Emory he was awarded a Bobby Jones Fellowship to pursue a M.Sc. in Physiology under the mentorship of Prof. Ian Johnson at the University of St. Andrews, Scotland. After obtaining his M.Sc. and raising his golf game from abysmal to lousy, he left St. Andrews and ultimately obtained a Ph.D. exploring the role of viruses in marine ecosystems under the mentorship of Prof. Rita R. Colwell at the University of Maryland. He was awarded a National Research Council fellowship for post-doctoral work investigating microbial degradation of chiral pesticides under the mentorship of David Lewis (U.S. Environmental Protection Agency) and Prof. Robert Hodson at the University of Georgia. He is now a Full Professor at the University of Delaware and the Deputy and Associate Dean for Research and Graduate Programs in the College of Agriculture and Natural Resources. In the lab he subjects his students to the endless toil of digging through metagenomic sequence data to expand understanding of the biological capabilities and ecological roles of viruses within natural ecosystems.
Dr. Renhong Yan received his Ph.D. degree in biochemical & structural biology from Tsinghua University mentored by Prof. Nieng Yan in 2019. He is a Postdoctoral Researcher at Westlake University focusing on the structure and function of membrane proteins. His major research interests are the human amino acid transporter complex and phospholipid metabolism regulators.
Dr. Yondola is Vice President, Research and Development at Calder Biosciences Inc. in Brooklyn, NY. Dr. Yondola has extensive training in virology and vaccine development and his work is currently focused on designing and developing conformationally stabilized recombinant subunit vaccines immunogens for respiratory syncytial virus and influenza virus. Calder utilizes a conformational stabilization technology based on targeted dityrosine crosslinks that are engineered into proteins/complexes in order to develop otherwise intractable vaccines. He obtained his Ph.D. from Stony Brook University where his work focused on the biochemical and biophysical characterization of the adenovirus E4-ORF3 protein and his postdoctoral training was at the Mt. Sinai Medical Center focusing on influenza virus biology and universal influenza virus vaccine development. Dr. Yondola, has been at Calder Biosciences since 2013, where he headed the universal influenza and respiratory syncytial virus vaccine programs, and now directs the company's research & development.
POSTER SUBMISSION GUIDELINES
Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.
SUBMIT YOUR ABSTRACT
Enter the following information to this Submission Form:
All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.
If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.
Questions? Email Posters@LabRoots.com
DiaSorin Molecular LLC manufactures and distributes molecular diagnostic products worldwide helping laboratories to streamline workflow and improve patient management. Our Simplexa® molecular kits include HSV-1 & 2, Flu A/B & RSV, Bordetella, VZV, Group A Strep, Group B ...See more See less
For 60 years The Baker Company has been at the forefront of engineering, testing and production of reliable laboratory contamination control equipment. Recognized as the industry pioneer, The Baker Company maintains an unparalleled passion for helping our customers advance ...See more See less
Millipore Sigma is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis ...See more See less
Luminex's mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and ...See more See less
The American Biological Safety Association (ABSA) was founded in 1984 to promote biosafety as a scientific discipline and serve the growing needs of biosafety professionals throughout the world. The Association's goals are to provide a professional association that represents the ...See more See less
Manuscriptedit specializes in providing services in Scientific & English editing, proofreading, medical writing, academic writing, formatting and publication support. Within a short span of time, the company has grown rapidly to be counted among the world's leading service ...See more See less
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner, and safer. We serve life science researchers from academic institutions and pharmaceutical industry, providing an unmatched combination of ...See more See less
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological ...See more See less
At MicroGEM, we have re-invented nucleic acid extraction. We replace traditional extraction methods with a temperature-driven, enzymatic approach, enabling high-quality extracts from low abundance transcripts and small sample volumes. Leveraging our prepGEM Universal thermophilic ...See more See less
PacBio® Systems are powered by Single Molecule, Real-Time (SMRT®) Sequencing and provide comprehensive views of genomes, transcriptomes, and epigenomes. As the only sequencing technology to offer highly accurate long reads, or HiFi reads, PacBio provides unparalleled access to ...See more See less
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here